Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study

Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study

BackgroundImatinib (IM) is the primary treatment for Gastrointestinal stromal tumor (GIST), but it faces significant challenges with resistance and a high incidence of adverse events. This study aims to assess the predictive value of baseline body composition parameters on treatment-related adverse...

Full description

Saved in:
Bibliographic Details
Main Authors: Tianhao Gu, Tengyun Li, Jianan Zhang, Qianzheng Zhou, Dinghua Yang, Jun Xu, Qiong Li, Zekuan Xu, Fengyuan Li, Hao Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
myosteatosis
CXI index
sarcopenia
treatment-related adverse events
disease-free survival
gastrointestinal stromal tumors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1576834/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1576834/full

Similar Items